TriangleNCT04824794 · OUTCOME
Dose Escalation and Expansion Part A: Area Under the Concentration Time Curve From Zero to Last Quantifiable Sample (AUC0-last) of GEN3014
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- GEOMETRIC_MEAN
- Unit
- day*ug/mL
- Interval / dispersion
- Geometric Coefficient of Variation
- Time frame
- Dose Escalation: Cycle 1 Day 1, Cycle 1 Day 8 (RRMM Dose Escalation: GEN3014 0.2/0.6 mg/kg only), Cycle 2 Day 1, Expansion Part A: Cycle 1 Day 1, Cycle 2 Day 1 (cycle =28 days)
What was measured
Venous blood samples were collected for analyzing concentrations of GEN3014. For the RRMM Dose Escalation 0.2/0.6 mg/kg arm, the participant underwent intraparticipant dose escalation in Cycle 1, where the participant received 0.2 mg/kg during the first week and 0.6 mg/kg from second week and beyond. Therefore, PK parameters were additionally calculated for Cycle 1 Day 8 dosing only in the RRMM Dose Escalation 0.2/0.6 mg/kg arm to account for the change in dosing over Cycle 1 in this arm.
Analysis population: PK Analysis Set=all participants exposed to GEN3014 with 1+ PK sample with a valid bioanalytical result. Overall number of participants analyzed=participants evaluable for the outcome measure. Number analyzed= participants evaluable at the specified timepoint.
Groups in this outcome
RRMM Dose Escalation: GEN3014 0.2/0.6 mg/kg
Participants with RRMM received GEN3014 at a dose of 0.2/0.6 mg/kg by IV infusion in 28-day treatment cycles. Intraparticipant dose escalation was performed in this arm (i.e., dose was escalated from 0.2-0.6 mg/kg).
RRMM Dose Escalation: GEN3014 2 mg/kg
Participants with RRMM received GEN3014 at a dose of 2 mg/kg by IV infusion in 28-day treatment cycles.
RRMM Dose Escalation: GEN3014 4 mg/kg
Participants with RRMM received GEN3014 at a dose of 4 mg/kg by IV infusion in 28-day treatment cycles.
RRMM Dose Escalation: GEN3014 8 mg/kg
Participants with RRMM received GEN3014 at a dose of 8 mg/kg by IV infusion in 28-day treatment cycles.
RRMM Dose Escalation: GEN3014 16 mg/kg
Participants with RRMM received GEN3014 at a dose of 16 mg/kg by IV infusion in 28-day treatment cycles.
RRMM Dose Escalation: GEN3014 24 mg/kg
Participants with RRMM received GEN3014 at a dose of 24 mg/kg by IV infusion in 28-day treatment cycles.
R/R AML Dose Escalation: GEN3014 Dose Level 1
Participants with R/R AML received GEN3014 at dose level 1 (low dose) in 28-day treatment cycles.
RRMM Expansion Part A: GEN3014
Participants with anti-CD38 mAb-naive RRMM received GEN3014 IV infusion at a dose of 16 mg/kg in 28-day cycles during Expansion Part A.
R/R DLBCL Expansion Part A: GEN3014
Participants with R/R DLBCL received GEN3014 IV infusion at a dose of 16 mg/kg in 28-day cycles during Expansion Part A.
| Group | Source count |
|---|---|
| RRMM Dose Escalation: GEN3014 0.2/0.6 mg/kg | 1 |
| RRMM Dose Escalation: GEN3014 2 mg/kg | 1 |
| RRMM Dose Escalation: GEN3014 4 mg/kg | 3 |
| RRMM Dose Escalation: GEN3014 8 mg/kg | 3 |
| RRMM Dose Escalation: GEN3014 16 mg/kg | 9 |
| RRMM Dose Escalation: GEN3014 24 mg/kg | 5 |
| R/R AML Dose Escalation: GEN3014 Dose Level 1 | 4 |
| RRMM Expansion Part A: GEN3014 | 11 |
| R/R DLBCL Expansion Part A: GEN3014 | 2 |
Reported measurements
Cycle 1 Day 1
| Group | Source count |
|---|---|
| RRMM Dose Escalation: GEN3014 0.2/0.6 mg/kg | 1 |
| RRMM Dose Escalation: GEN3014 2 mg/kg | 1 |
| RRMM Dose Escalation: GEN3014 4 mg/kg | 3 |
| RRMM Dose Escalation: GEN3014 8 mg/kg | 3 |
| RRMM Dose Escalation: GEN3014 16 mg/kg | 9 |
| RRMM Dose Escalation: GEN3014 24 mg/kg | 5 |
| R/R AML Dose Escalation: GEN3014 Dose Level 1 | 4 |
| RRMM Expansion Part A: GEN3014 | 11 |
| R/R DLBCL Expansion Part A: GEN3014 | 2 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| RRMM Dose Escalation: GEN3014 0.2/0.6 mg/kg | 3.760 | Not reported | Not reported | Not reported | Not reported |
| RRMM Dose Escalation: GEN3014 2 mg/kg | 38.200 | Not reported | Not reported | Not reported | Not reported |
| RRMM Dose Escalation: GEN3014 4 mg/kg | 134.091 | 62.311 | Not reported | Not reported | Not reported |
| RRMM Dose Escalation: GEN3014 8 mg/kg | 381.969 | 18.970 | Not reported | Not reported | Not reported |
| RRMM Dose Escalation: GEN3014 16 mg/kg | 705.626 | 31.171 | Not reported | Not reported | Not reported |
| RRMM Dose Escalation: GEN3014 24 mg/kg | 846.137 | 32.649 | Not reported | Not reported | Not reported |
| R/R AML Dose Escalation: GEN3014 Dose Level 1 | 54.705 | 578.106 | Not reported | Not reported | Not reported |
| RRMM Expansion Part A: GEN3014 | 367.708 | 197.983 | Not reported | Not reported | Not reported |
| R/R DLBCL Expansion Part A: GEN3014 | 693.711 | 35.138 | Not reported | Not reported | Not reported |
Cycle 1 Day 8
| Group | Source count |
|---|---|
| RRMM Dose Escalation: GEN3014 0.2/0.6 mg/kg | 1 |
| RRMM Dose Escalation: GEN3014 2 mg/kg | 0 |
| RRMM Dose Escalation: GEN3014 4 mg/kg | 0 |
| RRMM Dose Escalation: GEN3014 8 mg/kg | 0 |
| RRMM Dose Escalation: GEN3014 16 mg/kg | 0 |
| RRMM Dose Escalation: GEN3014 24 mg/kg | 0 |
| R/R AML Dose Escalation: GEN3014 Dose Level 1 | 0 |
| RRMM Expansion Part A: GEN3014 | 0 |
| R/R DLBCL Expansion Part A: GEN3014 | 0 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| RRMM Dose Escalation: GEN3014 0.2/0.6 mg/kg | 19.900 | Not reported | Not reported | Not reported | Not reported |
Cycle 2 Day 1
| Group | Source count |
|---|---|
| RRMM Dose Escalation: GEN3014 0.2/0.6 mg/kg | 1 |
| RRMM Dose Escalation: GEN3014 2 mg/kg | 1 |
| RRMM Dose Escalation: GEN3014 4 mg/kg | 3 |
| RRMM Dose Escalation: GEN3014 8 mg/kg | 3 |
| RRMM Dose Escalation: GEN3014 16 mg/kg | 9 |
| RRMM Dose Escalation: GEN3014 24 mg/kg | 2 |
| R/R AML Dose Escalation: GEN3014 Dose Level 1 | 2 |
| RRMM Expansion Part A: GEN3014 | 8 |
| R/R DLBCL Expansion Part A: GEN3014 | 1 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| RRMM Dose Escalation: GEN3014 0.2/0.6 mg/kg | 29.300 | Not reported | Not reported | Not reported | Not reported |
| RRMM Dose Escalation: GEN3014 2 mg/kg | 65.200 | Not reported | Not reported | Not reported | Not reported |
| RRMM Dose Escalation: GEN3014 4 mg/kg | 201.123 | 87.182 | Not reported | Not reported | Not reported |
| RRMM Dose Escalation: GEN3014 8 mg/kg | 664.850 | 21.702 | Not reported | Not reported | Not reported |
| RRMM Dose Escalation: GEN3014 16 mg/kg | 1068.278 | 46.176 | Not reported | Not reported | Not reported |
| RRMM Dose Escalation: GEN3014 24 mg/kg | 1127.573 | 43.127 | Not reported | Not reported | Not reported |
| R/R AML Dose Escalation: GEN3014 Dose Level 1 | 181.997 | 0.777 | Not reported | Not reported | Not reported |
| RRMM Expansion Part A: GEN3014 | 623.225 | 251.620 | Not reported | Not reported | Not reported |
| R/R DLBCL Expansion Part A: GEN3014 | 1340.000 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 3.760
- group Id
- OG001
- value
- 38.200
- group Id
- OG002
- spread
- 62.311
- value
- 134.091
- group Id
- OG003
- spread
- 18.970
- value
- 381.969
- group Id
- OG004
- spread
- 31.171
- value
- 705.626
- group Id
- OG005
- spread
- 32.649
- value
- 846.137
- group Id
- OG006
- spread
- 578.106
- value
- 54.705
- group Id
- OG007
- spread
- 197.983
- value
- 367.708
- group Id
- OG008
- spread
- 35.138
- value
- 693.711
- denoms
- counts
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 1
- group Id
- OG002
- value
- 3
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 9
- group Id
- OG005
- value
- 5
- group Id
- OG006
- value
- 4
- group Id
- OG007
- value
- 11
- group Id
- OG008
- value
- 2
- units
- Participants
- title
- Cycle 1 Day 1
- categories
- measurements
- group Id
- OG000
- value
- 19.900
- denoms
- counts
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 0
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 0
- group Id
- OG006
- value
- 0
- group Id
- OG007
- value
- 0
- group Id
- OG008
- value
- 0
- units
- Participants
- title
- Cycle 1 Day 8
- categories
- measurements
- group Id
- OG000
- value
- 29.300
- group Id
- OG001
- value
- 65.200
- group Id
- OG002
- spread
- 87.182
- value
- 201.123
- group Id
- OG003
- spread
- 21.702
- value
- 664.850
- group Id
- OG004
- spread
- 46.176
- value
- 1068.278
- group Id
- OG005
- spread
- 43.127
- value
- 1127.573
- group Id
- OG006
- spread
- 0.777
- value
- 181.997
- group Id
- OG007
- spread
- 251.620
- value
- 623.225
- group Id
- OG008
- value
- 1340.000
- denoms
- counts
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 1
- group Id
- OG002
- value
- 3
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 9
- group Id
- OG005
- value
- 2
- group Id
- OG006
- value
- 2
- group Id
- OG007
- value
- 8
- group Id
- OG008
- value
- 1
- units
- Participants
- title
- Cycle 2 Day 1
- denoms
- counts
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 1
- group Id
- OG002
- value
- 3
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 9
- group Id
- OG005
- value
- 5
- group Id
- OG006
- value
- 4
- group Id
- OG007
- value
- 11
- group Id
- OG008
- value
- 2
- units
- Participants
- description
- Venous blood samples were collected for analyzing concentrations of GEN3014. For the RRMM Dose Escalation 0.2/0.6 mg/kg arm, the participant underwent intraparticipant dose escalation in Cycle 1, where the participant received 0.2 mg/kg during the first week and 0.6 mg/kg from second week and beyond. Therefore, PK parameters were additionally calculated for Cycle 1 Day 8 dosing only in the RRMM Dose Escalation 0.2/0.6 mg/kg arm to account for the change in dosing over Cycle 1 in this arm.
- dispersion Type
- Geometric Coefficient of Variation
- groups
- description
- Participants with RRMM received GEN3014 at a dose of 0.2/0.6 mg/kg by IV infusion in 28-day treatment cycles. Intraparticipant dose escalation was performed in this arm (i.e., dose was escalated from 0.2-0.6 mg/kg).
- id
- OG000
- title
- RRMM Dose Escalation: GEN3014 0.2/0.6 mg/kg
- description
- Participants with RRMM received GEN3014 at a dose of 2 mg/kg by IV infusion in 28-day treatment cycles.
- id
- OG001
- title
- RRMM Dose Escalation: GEN3014 2 mg/kg
- description
- Participants with RRMM received GEN3014 at a dose of 4 mg/kg by IV infusion in 28-day treatment cycles.
- id
- OG002
- title
- RRMM Dose Escalation: GEN3014 4 mg/kg
- description
- Participants with RRMM received GEN3014 at a dose of 8 mg/kg by IV infusion in 28-day treatment cycles.
- id
- OG003
- title
- RRMM Dose Escalation: GEN3014 8 mg/kg
- description
- Participants with RRMM received GEN3014 at a dose of 16 mg/kg by IV infusion in 28-day treatment cycles.
- id
- OG004
- title
- RRMM Dose Escalation: GEN3014 16 mg/kg
- description
- Participants with RRMM received GEN3014 at a dose of 24 mg/kg by IV infusion in 28-day treatment cycles.
- id
- OG005
- title
- RRMM Dose Escalation: GEN3014 24 mg/kg
- description
- Participants with R/R AML received GEN3014 at dose level 1 (low dose) in 28-day treatment cycles.
- id
- OG006
- title
- R/R AML Dose Escalation: GEN3014 Dose Level 1
- description
- Participants with anti-CD38 mAb-naive RRMM received GEN3014 IV infusion at a dose of 16 mg/kg in 28-day cycles during Expansion Part A.
- id
- OG007
- title
- RRMM Expansion Part A: GEN3014
- description
- Participants with R/R DLBCL received GEN3014 IV infusion at a dose of 16 mg/kg in 28-day cycles during Expansion Part A.
- id
- OG008
- title
- R/R DLBCL Expansion Part A: GEN3014
- param Type
- GEOMETRIC_MEAN
- population Description
- PK Analysis Set=all participants exposed to GEN3014 with 1+ PK sample with a valid bioanalytical result. Overall number of participants analyzed=participants evaluable for the outcome measure. Number analyzed= participants evaluable at the specified timepoint.
- reporting Status
- POSTED
- time Frame
- Dose Escalation: Cycle 1 Day 1, Cycle 1 Day 8 (RRMM Dose Escalation: GEN3014 0.2/0.6 mg/kg only), Cycle 2 Day 1, Expansion Part A: Cycle 1 Day 1, Cycle 2 Day 1 (cycle =28 days)
- title
- Dose Escalation and Expansion Part A: Area Under the Concentration Time Curve From Zero to Last Quantifiable Sample (AUC0-last) of GEN3014
- type
- SECONDARY
- unit Of Measure
- day*ug/mL
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice